Repligen Stock Price, News & Analysis

Repligen Corporation (NASDAQ:RGEN) will present at the Barclays Global Healthcare Conference from March 9-11, 2021. CFO Jon Snodgres is scheduled for a fireside chat on March 10 at 1:50 p.m. EST. A live webcast of this discussion will be available on the Company’s Investor Relations website and will be accessible for replay afterwards. Repligen specializes in innovative bioprocessing technologies for the biopharmaceutical industry, enhancing drug manufacturing efficiency globally.

Repligen Corporation (NASDAQ:RGEN) reported strong fourth quarter 2020 results with revenues of $108.6 million, a 56% year-over-year increase, driven by sales to COVID vaccine accounts. Total annual revenue reached $366.3 million, up 36% year-over-year. Operating income was $17.4 million, a significant rise, with a GAAP EPS of $0.36. For 2021, Repligen projects revenue between $500-$525 million, reflecting a 37%-43% growth rate.

Repligen Corporation (NASDAQ:RGEN) will present virtually at the 10th Annual SVB Leerink Healthcare Conference from February 22-26, 2021. Tony J. Hunt, the President and CEO, is scheduled to participate in a fireside chat on February 26 at 12:00 p.m. EST. Investors can access a live webcast and replay through the Company’s Investor Relations website. Repligen specializes in bioprocessing technologies that enhance the manufacturing of biological drugs, catering mainly to biopharmaceutical developers globally.

Repligen Corporation (NASDAQ:RGEN) has announced a webcast and conference call to discuss its fourth quarter and full year 2020 financial results, scheduled for February 24, 2021 at 8:30 a.m. EST. The financial report will be released before the market opens. Interested parties can join the call by dialing 844-274-3999 for domestic callers or 412-317-5607 for international callers. Repligen develops innovative bioprocessing technologies for biopharmaceutical manufacturers globally and has facilities in various countries including the U.S., Estonia, Germany, and Sweden.

Repligen Corporation (NASDAQ:RGEN) and Navigo Proteins GmbH have announced the commercial launch of the NGL COVID-19 Spike Protein Affinity Resin, designed to enhance the purification process of COVID-19 vaccines. This resin aims to provide a high-purity capture step, reducing processing time and improving yield. The resin meets high-performance standards, including selectivity and dynamic binding capacities. Positive customer feedback has been recorded, with orders for validated resins currently being accepted.

Repligen Corporation (NASDAQ:RGEN) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. CEO Tony J. Hunt will present on January 13 at 9:10 a.m. EST. A live webcast of the presentation will be available on the Company’s investor relations website and will be accessible for replay afterward.

The company, based in Waltham, Massachusetts, focuses on bioprocessing technologies aimed at improving the efficiency of manufacturing biological drugs, serving biopharmaceutical developers and CDMOs globally.

Repligen Corporation (NASDAQ: RGEN) successfully closed its underwritten public offering of 1.725 million shares at $181 each, generating gross proceeds of approximately $312.2 million. After deducting fees, the net proceeds are expected to be about $298 million, intended for working capital and general corporate purposes, including potential investments in complementary businesses. The offering included full exercise of the underwriters’ option for an additional 225,000 shares. The company has no current agreements for acquisitions.

EC Mergers & Acquisitions has announced the successful sale of ARTeSYN BioSolutions to Repligen Corporation for a total transaction value of $200M. This includes $130M in cash and $70M in Repligen common stock. ARTeSYN specializes in single-use solutions for bioprocessing, anticipating $30M in pro forma revenue for 2020. The acquisition is expected to generate approximately $33M-$36M in revenue for Repligen in 2021, enhancing its portfolio in bioprocessing technologies.

Repligen Corporation (NASDAQ: RGEN) has priced a public offering of 1.5 million shares at $181 each, aiming to raise approximately $271.5 million before expenses. The underwriters hold a 30-day option for an additional 225,000 shares. Proceeds will be used for working capital and general corporate purposes, including potential acquisitions and investments. The offering is scheduled to close around December 10, 2020, pending customary conditions. J.P. Morgan and Stifel are the lead managers of the offering.